These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27123192)

  • 1. The value of innovation under value-based pricing.
    Moreno SG; Ray JA
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the "Age of Cures" and Their Implications for Dynamic Efficiency.
    Garrison LP; Jiao B; Dabbous O
    Value Health; 2023 Mar; 26(3):336-343. PubMed ID: 36336584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework.
    Moreno SG; Epstein D
    J Mark Access Health Policy; 2019; 7(1):1583536. PubMed ID: 30956782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need.
    Dionne PA; Ali F; Grobler M
    J Health Econ Outcomes Res; 2015; 3(1):13-23. PubMed ID: 34430665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of Incorporating Life Cycle Drug Pricing in Cost-Effectiveness Models: A Review of Methods and Modeling Suggestions.
    Puls M; Horscroft J; Kearns B; Gladwell D; Church E; Johannesen K; Malcolm B; Borrill J
    Value Health; 2024 Jul; 27(7):978-985. PubMed ID: 38513883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.
    Schöttler MH; Coerts FB; Postma MJ; Boersma C; Rozenbaum MH
    Value Health; 2023 Jan; 26(1):91-98. PubMed ID: 35933271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the price right? Paying for value today to get more value tomorrow.
    Ramagopalan SV; Diaz J; Mitchell G; Garrison LP; Kolchinsky P
    BMC Med; 2024 Jan; 22(1):45. PubMed ID: 38287326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Generalized Cost-effectiveness Analysis Leverage Meaningful Use of Novel Value Elements in Pharmacoeconomics to Inform Medicare Drug Price Negotiation?
    Padula WV; Kolchinsky P
    Value Health; 2024 Apr; ():. PubMed ID: 38677362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis.
    Obeng-Kusi M; Erstad B; Roe DJ; Abraham I
    J Med Econ; 2022; 25(1):894-902. PubMed ID: 35748085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
    Goldhaber-Fiebert JD; Cipriano LE
    Med Decis Making; 2023; 43(7-8):914-929. PubMed ID: 37698120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing.
    Alkhatib NS; Ramos K; Erstad B; Slack M; McBride A; Bhattacharjee S; Abraham I
    J Med Econ; 2020 Nov; 23(11):1215-1222. PubMed ID: 32845794
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.